X
https://www.indianpharmapost.com/news/abbvies-phase-3-select-gca-study-of-upadacitinib-showed-positive-results-in-patients-with-giant-cell-arteritis-15560
https://www.reuters.com/business/healthcare-pharmaceuticals/us-cdc-warns-harmful-reactions-fake-botox-injections-2024-04-23/
https://www.biopharmadive.com/news/cerevel-parkinsons-tavapadon-study-results-abbvie/713566/
https://www.fiercepharma.com/marketing/abbvie-tops-jj-drops-physicians-rank-immunology-players
https://www.fiercepharma.com/pharma/abbvie-touts-rinvoq-win-giant-cell-arteritis-potentially-teeing-another-label-expansion
https://www.prnewswire.com/news-releases/phase-3-select-gca-study-of-upadacitinib-rinvoq-showed-positive-results-in-patients-with-giant-cell-arteritis-302120893.html
https://www.medincell.com/wp-content/uploads/2024/04/CP_MDC_strategic-agreement-AbbVie_April-2024_EN.pdf
https://www.fiercepharma.com/pharma/boehringer-ingelheim-leans-late-stage-pipeline-plots-25-new-launches-over-next-decade
https://www.prnewswire.com/news-releases/abbvie-announces-late-breaking-data-at-aan-supporting-long-term-safety-and-efficacy-of-atogepant-qulipta-for-preventive-treatment-of-migraine-302114992.html
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-supernus-drug-device-combination-parkinsons-disease-2024-04-08/
Market Place
Share 
